Localized oligonucleotide therapy

• US 5,593,974 A
• Filed: 01/06/1995
• Issued: 01/14/1997
• Est. Priority Date: 06/28/1991
• Status: Expired due to Fees

• Current Assignee: Massachusetts Institute of Technology
• Original Assignee: Massachusetts Institute of Technology
• Inventors: Rosenberg, Robert D., DeKeyser, Jean-Luc, Edelman, Elazer, Langer, Robert S., Simons, Michael
• Primary Examiner(s): Campell, Bruce R.
• Application Number:
  US08/369,282
• Time in Patent Office: 739 Days
• Field of Search: 514/44, 424/423, 424/428, 424/426, 424/486, 536/24.5, 604/52, 604/53, 604/890.1, 935/44, 935/52
• US Class Current: 514/44.00A
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/315 Phosphorothioates

Abstract

Disclosed is a method for localized application of antisense oligonucleotides, which has been found to be effective in inhibiting expression and translation of a variety of genes. The method utilizes antisense oligonucleotides which are specific for the mRNA transcribed from the gene of interest. The antisense oligonucleotides are applied directly to the desired locus of the cells to be treated, where they hybridize with the mRNA and inhibit expression of the gene. Devices for localized antisense application and methods for making them also are described.

Claims

1. A method of inhibiting translation of a target nucleic acid sequence preferentially at a vascular tissue locus in vivo to thereby inhibit restenosis at said locus, the method comprising:

directly applying to said vascular tissue locus within the body of a mammal an antisense oligonucleotide, comprising 14 to 38 nucleotide bases, that is complementary to a target nucleic acid sequence expressed in smooth muscle cells and necessary to initiate a target nucleic acid sequence expressed in smooth muscle cells and necessary to initiate or support proliferation thereof, in an amount sufficient to penetrate smooth muscle cells of the tissue at said locus, to hybridize with said target nucleic acid, and to inhibit intracellular translation of said target sequence to thereby inhibit restenosis at said locus, wherein said target nucleic acid is a gene coding for a protein selected from the group consisting of c-myb, NMMHC and PCNA.

2. The method of claim 1 wherein the oligonucleotide is in a physiologically compatible solution and wherein it is applied by injection.

3. The method of claim 1 wherein the solution is applied to the tissue using an infusion pump, stent, or catheter.

4. The method of claim 1 wherein the oligonucleotide is treated to render it resistant to degradation or extension by intracellular enzymes.

5. The method of claim 4 wherein the treatment comprises substituting at least one backbone phosphodiester linkage of the oligonucleotide with a linkage selected from the group consisting of phosphorothioate, methylphosphonate, sulfone, sulfate, ketyl, phosphorodithioate, phosphoramidate, phosphate ester, bridged phosphorothioate and bridged phosphoramidate linkages.

6. The method of claim 4 wherein the treatment comprises capping a 3'"'"'-nucleotide with a structure resistant to addition of nucleotides.

7. The method of claim 1 wherein the oligonucleotide is delivered to the tissue in a concentration of between approximately 30 and 3000 μ

g oligonucleotide per square centimeter of tissue surface area.

8. The method of claim 1 wherein the target nucleic acid sequence comprises an mRNA.

9. A method of inhibiting translation of a target nucleic acid sequence preferentially at a vascular tissue locus in vivo to thereby inhibit restenosis at said locus, the method comprising:

directly depositing onto a surface of a vascular tissue locus within the body of a mammal an antisense oligonucleotide of 14 to 38 nucleotide bases that is complementary to a target nucleic acid sequence expressed in smooth muscle cells and necessary to initiate or support proliferation thereof, said oligonucleotide being incorporated within a carrier; and

permitting the oligonucleotide to penetrate from said carrier into smooth muscle cells of the tissue at said locus in an amount sufficient to hybridize with said target nucleic acid and to inhibit intracellular translation thereof to inhibit restenosis at said locus, wherein the target nucleic acid comprises an mRNA sequence transcribed from a gene coding for a protein selected from the group consisting of c-myb, NMMHC and PCNA.

10. The method of claim 9 wherein the carrier comprises an implantable matrix.

11. The method of claim 9 wherein the carrier comprises a hydrogel.

12. The method of claim 11 wherein the hydrogel comprises a material which is liquid at a temperature below about 37°

C.

13. The method of claim 12 wherein the hydrogel material comprises a polyethylene oxide-polypropylene oxide polymer.

14. The method of claim 13 wherein the polymer comprises from about 10 to about 80% by weight polyethylene oxide and from about 20 to about 90% by weight polypropylene oxide.

15. The method of claim 14 wherein the polymer comprises about 70% by weight polyethylene oxide and about 30% by weight polypropylene oxide.

16. The method of claim 9 wherein the oligonucleotide, incorporated within said carrier, is deposited extravascularly.

17. The method of claim 9 wherein said oligonucleotide, incorporated within said carrier, is deposited onto or beneath an adventitial surface of the vascular system.

18. A method for inhibiting restenosis at a vascular tissue locus following injury to the locus, the method comprising:

directly applying to the locus of a vascular tissue injury in vivo an antisense oligonucleotide, complementary to a target nucleic acid expressed in smooth muscle cells and necessary to initiate or support proliferation thereof, the oligonucleotide being applied at a concentration sufficient to permit the oligonucleotide to penetrate smooth muscle cells at the locus, and to induce selective hybridization between said nucleic acid and said antisense oligonucleotide within the smooth muscle cells for a time sufficient to inhibit restenosis at the locus of the vascular tissue injury, wherein the target nucleic acid comprises a portion of an mRNA encoding a protein selected from the group consisting of a c-myb protein, non-muscle myosin heavy chain and PCNA.

19. A method for inhibiting restenosis at a vascular tissue locus following injury to said locus, the method comprising:

directly applying to the locus of a vascular tissue injury in vivo a hydrogel, which is liquid below about 37°

C. and gels at body temperature, the hydrogel having incorporated therein an antisense oligonucleotide, complementary to a target nucleic acid expressed in smooth muscle cells and necessary to initiate or support proliferation thereof; and

permitting the oligonucleotide present in the hydrogel to diffuse from the hydrogel at a concentration sufficient to permit the oligonucleotide to penetrate smooth muscle cells at the tissue locus and to hybridize with the target nucleic acid for a time sufficient to inhibit restenosis at the locus of the vascular tissue injury, wherein the target nucleic acid comprises a portion of a mRNA encoding a protein selected from the group consisting of a c-myb protein, non-muscle myosin heavy chain and PCNA.

20. The method of claim 19 wherein said hydrogel comprises a polymer of ethylene oxide-propylene oxide repeating units.